Evolocumab to impact coronary disease in statin-treated patients: Glasgov Trial

A total of 968 patients (mean age, 60 years; 72% male) presenting for coronary angiography were enrolled in this trial, which was conducted at 197 academic and community hospitals in North America, Europe, South America, Asia, Australia, and South Africa. Those with angiographic disease (20-50% stenosis in a target coronary vessel) were randomly assigned to receive monthly evolocumab 420 mg subcutaneously or matching subcutaneous placebo injection for 76 weeks, in addition to a stable, optimized statin dose.

This is the first clinical trial, according to authors to show incremental effects on regression in patients who had been treated with moderate or intensive statin therapy prior to entry into the study. It is also the first to demonstrate a reduction in atherosclerotic disease progression by IVUS for a nonstatin LDL-C-lowering therapy concluded the auhors.